Business Wire

Mercans Launches Groundbreaking AI Suite, Redefining Payroll as an Intelligent, Always-On Business Function

Share

From real-time payroll to compliance automation, Mercans positions itself as the world’s first truly AI-first payroll company

Mercans, a global leader in payroll technology and managed payroll services, today unveiled a sweeping suite of AI-powered innovations that mark a historic shift in the payroll industry. With this launch, Mercans positions itself not as a company with AI features, but as an AI-first organization, embedding intelligence into the very core of payroll, compliance, and client experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006939644/en/

AI-powered payroll. Smarter. Faster. Always compliant (Graphic: AETOSWire)

“Payroll has long been seen as a back-office necessity. We are turning it into a front-line strategic advantage. By putting AI at the center of our platform, we’re delivering accuracy, compliance, and insights at a scale and speed never before possible. This is not just about functionality - it’s about redefining payroll’s role in business.”
- Tatjana Domovits, Group CEO of Mercans.

Paradigm Shift In How Payroll Is Run And Experienced

Mercans is transforming the payroll experience with a suite of AI capabilities that redefines how payroll is calculated, validated, reported, and understood.

Central to this transformation is Instaroll™, the company’s real-time payroll orchestration engine that allows organizations to simulate, calculate, and adjust payroll instantly. Employees can now see their earnings outcomes as they happen, while finance leaders gain unparalleled visibility into workforce costs. With Instaroll, payroll moves from a rigid monthly cycle into a dynamic, on-demand process.

One of the most powerful demonstrations of Mercans’ AI-first vision is I/O Validation, a feature built into the core platform and available to all clients. It is a true game changer because it solves one of payroll’s most persistent pain points: ensuring that what goes in and what comes out of payroll is always correct. Traditional payroll systems rely on rigid rule-based checks that often miss contextual errors - a misplaced overtime calculation, an incorrect tax rate, or a mismatched contribution. With AI-driven I/O Validation, these issues are detected instantly. The system continuously learns from payroll patterns, cross-checks both inputs and outputs, and flags anomalies before they reach employees or regulators.

By embedding this intelligence natively into the platform, Mercans makes proactive accuracy a guaranteed standard for every Managed Payroll and SaaS client. This is not an add-on, it is a practical application of AI that delivers trust, saves time, and eliminates costly mistakes.

Another breakthrough AI capability in the Mercans platform is Custom Reporting AI, which transforms payroll data from static numbers into living intelligence. Instead of being limited to pre-defined templates, leaders can simply ask the system questions in natural language such as “Show me overtime costs by region for the past three quarters”, and instantly receive tailored, interactive reports. The AI doesn’t just fetch data; it interprets patterns, highlights anomalies, and presents findings in executive-ready formats.

This means payroll data is no longer a historical record, it becomes a forward-looking decision-making tool. Combined with Mercans’ built-in I/O Validation, which ensures that the data itself is accurate, Custom Reporting AI makes payroll not only correct but also actionable. Executives can spot workforce trends, anticipate risks, and model financial impacts with confidence, turning payroll from a compliance task into a strategic intelligence engine.

On the employee side, one of the most visible and practical applications of Mercans’ AI is the Payslip Interpretation Assistant. Available 24/7, this AI companion translates complex payslips into clear, simple language - explaining taxes, deductions, and allowances in a way that anyone can understand. What used to be a source of confusion and repeated HR queries is now resolved instantly, on demand.

Compliance Without Borders

Regulatory compliance remains one of the most formidable challenges for global enterprises. With Mercans’ AI Compliance Hub, clients now benefit from real-time monitoring of legislation across the globe. This AI-driven system not only interprets legal changes but proactively guides organizations to remain ahead of regulatory risks.

Complementing this is the Statutory Filing Status & Summary Assistant, which gives finance leaders instant visibility into filing obligations across jurisdictions. Whether it’s a quarterly tax submission in Europe or a statutory report in Asia, AI ensures deadlines and statuses are tracked with precision, transforming compliance from reactive firefighting into proactive assurance.

Intelligent Support, Always Available

In addition to transforming payroll operations, Mercans has embedded AI into its support ecosystem. The company has launched dedicated AI Agents for Technical and Product Support, designed to provide immediate, intelligent responses to client inquiries. These agents not only resolve issues in real time but also escalate complex cases intelligently, dramatically reducing resolution times and enhancing customer satisfaction. For clients, this means uninterrupted operations and a support experience that feels less like troubleshooting and more like a partnership.

The Mercans Advantage

The cumulative impact of these innovations is profound. For Managed Payroll clients, it means lower costs, fewer errors, and proactive compliance, delivered with intelligence at every step. For SaaS platform clients, it represents a new era of self-service, where AI copilots provide instant insights, compliance takes care of itself, and payroll becomes a strategic lever rather than a burdensome process.

“Payroll has always been about compliance and accuracy. Today, it is about intelligence, foresight, and empowerment,” added Tatjana Domovits, Group CEO of Mercans. “We are not just keeping pace with change - we are leading it. Mercans is unstoppable in its mission to transform payroll into the most intelligent business function of the future.”

About Mercans

Mercans is a leading global payroll technology company, delivering compliant, efficient, and scalable payroll solutions to multinational organizations. With a relentless focus on innovation, automation, and client success, Mercans continues to set the benchmark for the future of payroll. visit www.mercans.com
LinkedIn

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251006939644/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III6.10.2025 14:00:00 CEST | Press release

TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors and new institutional investors, foundations, pensions, and endowments. With the close of Fund III, TCGX has now raised more than $3.1 billion in total capital since its founding in 2021. TCGX Fund III exceeded its initial target, underscoring strong global investor demand. The fundraise marks a significant milestone and is an endorsement of the differentiated strategy and TCGX’s fully flexible mandate to invest across both private and public markets. “Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.” “We are grateful t

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting6.10.2025 13:05:00 CEST | Press release

Furthers Global Leadership in Donor Organ and Transplant Recipient HLA Typing CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society for Histocompatibility and Immunogenetics (ASHI) 2025 Annual Meeting, held October 6th to 10th in Orlando, Florida. The company also announced that its AlloSeq® Tx and QTYPE® products have received certification for compliance to the In Vitro Diagnostic Regulation (IVDR) in the European Union. “This week at ASHI 2025, we will highlight our continued investment in creating life changing solutions that allow transplant patients to thrive,” said John Hanna, President and Chief Executive Officer. “The new product innovations and regulatory milestone underscore CareDx’s co

INVESTMENT FORUM - Senegal Is Betting on Forum Invest in Senegal 2025 (Fii 2025) to Accelerate the Inflow of Foreign Capital6.10.2025 11:59:00 CEST | Press release

In 2024, the country attracted nearly $3 billion in FDI, primarily in energy and infrastructure, according to official data As the landscape of foreign direct investment (FDI) flows into Africa is being reshaped, Senegal aims to capture a growing share of this capital through the Forum Invest in Senegal 2025 (Fii Senegal 2025) (http://apo-opa.co/3KzxBkp), which opens on Tuesday in Diamniadio. “Senegal is positioning itself as a crossroads between Africa and the rest of the world, a gateway for attracting capital, technology, and expertise,” explains Bakary Séga Bathily, Director General of APIX, the agency responsible for investment promotion and major infrastructure projects. With the central theme of ‘connecting opportunities, building the future,’ the event—held under the patronage of His Excellency, President Bassirou Diomaye Diakhar Faye—aims to showcase a portfolio of strategic projects across three key sectors: Energy: The development of natural gas from Yakaar-Teranga, combined

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study6.10.2025 11:43:00 CEST | Press release

Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept study results of topical bimiralisib gel (2%) for the treatment of actinic keratosis (AK) at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, the largest dermatology conference in Europe. The randomized, multi-center study evaluated topical bimiralisib gel as a field-directed treatment for AK on the face, scalp, and/or back of hands. Results demonstrated substantial efficacy and a favorable safety profile, supporting further clinical development: Efficacy: 92% ofcomplete or near complete response withOlsen grade 1 patients, and overall, 52% of patients in the 2-week period and 71% in the 4-week period achieved an Investigator’s Global Assessment (IGA) score of 0–1 (complete or partial clearance)

Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions6.10.2025 11:00:00 CEST | Press release

Switching from intravenous (IV) to subcutaneous (SC) infliximab was shown to be well tolerated, with a low relapse risk for most IBD patients and high treatment persistence1, 2 Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in patients with inflammatory bowel disease (IBD). The real-world evidence was presented at the Meet the Expert (MTE) Sessions at UEG 2025, and included presentations from Professor Nicolas Mathieu, Medical Director of MICI Institut Privé, Cliniques des Cèdres and Associate Professor of Gastroenterology, and Prof Anthony Buisson, Head of IBD Unit at University Hospital Estaing, Clermont Ferrand, France. Professor Nicolas Mathieu presented a real-life study which demonstrated that the switch from IV infliximab to SC infliximab is well tolerated amongst patients. The presentation particularly highlighted the results from the m

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye